Collaborative Research and License Agreements - Additional Information (Detail) - USD ($)		1 Months Ended				12 Months Ended
	Jan. 24, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from Incyte Share Purchase Agreement shares	86,000	12,432,431	7,840,909	3,802,144
Aggregate purchase price				$ 81,200,000
Common stock issued at fair value						$ 24,848,000
Collaboration receivable, net		$ 0	$ 3,474,000
Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from Incyte Share Purchase Agreement shares				1,421,523
Purchase price per share				$ 24.62		$ 24.62
Aggregate purchase price				$ 35,000,000
Common stock issued at fair value				24,800,000
Allocated consideration received to derivative liability				600,000
Upfront payments returned upon termination of agreement				117,000,000
Total transaction price				126,600,000
Estimated standalone selling price of license agreement				126,600,000
Revenue recognized upon transfer of license agreement						$ 126,600,000
Collaboration receivable, net		2,200,000
Collaboration expense due to counterparty		$ 9,500,000
Incyte Agreement [Member] | Non-Refundable Cash Payments [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront milestone payable				117,000,000	$ 117,000,000
Incyte Agreement [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential milestone payments to be made				220,000,000		220,000,000
Commercialization milestones and tiered royalties				$ 230,000,000		$ 230,000,000
Incyte Agreement [Member] | Global and U.S. [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials					45.00%
Incyte Agreement [Member] | Global and U.S. [Member] | Incyte Corporation [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials					55.00%
Incyte Agreement [Member] | Ex-U.S. Countries [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials					100.00%